Exudative retinopathy from retinal vasoproliferative tumor refractory to aflibercept treated with faricimab-svoa

To report a case of exudative retinopathy secondary to retinal vasoproliferative tumor (RVPT) refractory to aflibercept treated with faricimab-svoa (faricimab).

A 43-year-old female presented with an exudative and hemorrhagic lesion in the periphery of the right eye consistent with RVPT. She was treated initially with three aflibercept injections every 4-6 weeks. Despite treatment, her exam worsened with increased exudation and subretinal fluid. She was then treated with five monthly faricimab injections, which resulted in resolution of subretinal fluid and exudates, and near complete regression of the RVPT. The patient subsequently developed a retinal tear at the base of the RVPT that was successfully treated with laser retinopexy. At one year follow-up, the RVPT remained fully regressed. She was monitored off therapy. No adverse event was noted.

Faricimab has potential utility in treating exudative retinopathy secondary to RVPT. Further investigation with treatment trials and long-term follow-up is warranted.